会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • CANCER PROGNOSIS USING THYMOSIN beta10 (Tbeta10)
    • 使用THYMOSIN beta10(Tbeta10)的癌症预防
    • WO03046582A8
    • 2003-08-07
    • PCT/GR0200060
    • 2002-11-28
    • NAT CT SCIENT RES DEMOKRITOSFARAN LAB S AAPOSTOLIKAS NIKIFOROSEVANGELATOS GRIGORIOSITHAKISSIOS XANTHI HFLEONDIADIS LEONDIOSLIVANIOU EVANGELIAVERGHESE-NIKOLAKAKI SUSANA
    • APOSTOLIKAS NIKIFOROSEVANGELATOS GRIGORIOSITHAKISSIOS DIONYSIOS DILEONDIADIS LEONDIOSLIVANIOU EVANGELIAVERGHESE-NIKOLAKAKI SUSANA
    • G01N33/574G01N33/68
    • G01N33/574G01N2333/5759
    • The invention presents a reliable specific immunohistochemical method, which uses thymosin beta10 as a cancer marker with application in the confirmation of diagnosis and prognosis of cancer, and provides guidance for the evaluation of positivity of immunohistochemical expression of thymosin beta10 in benign and malignant tissues. The evaluation of the measured Tbeta10 expression is characterized by the fact that Tbeta10 expression is correlated with the aggressiveness of the disease, and this correlation is based on the concept that: the weaker the expression of Tbeta10 in cancer cells, the higher the aggressiveness of the neoplasm and vice versa, that is: the stronger the expression of Tbeta10 in cancer cells, the lower the aggressiveness of the neoplasm. The invention also describes an in vitro diagnostic kit, which, by application of the above-described concept of evaluation of Tbeta10 expression, provides a means of confirmation of cancer diagnosis and a means of reliable prognosis of its course, and is therefore useful for the better therapeutic handling of cancer. The above method and kit are also applicable in the evaluation of the measurement of other known alpha - and beta-thymosins, such as thymosin beta9 (Tbeta9), thymosin beta4 (Tbeta4), thymosin beta15 (Tbeta15), thymosin alpha1 (Tbeta1), prothymosin (ProTalpha) and parathymosin (ParaTalpha).
    • 本发明提供了一种可靠的特异性免疫组织化学方法,其使用胸腺素β10作为癌症标志物,用于确认癌症的诊断和预后,为评估胸腺素β10在良性和恶性组织中的免疫组织化学阳性表达提供指导。 测量的Tbeta10表达的评估的特征在于Tbeta10表达与疾病的侵袭性相关,并且这种相关性基于以下概念:癌细胞中Tbeta10的表达越弱,侵袭性越高 肿瘤,反之亦然,即:Tbeta10在癌细胞中的表达越强,肿瘤侵袭性越低。 本发明还描述了一种体外诊断试剂盒,其通过应用上述Tbeta10表达评估概念提供了确认癌症诊断的手段和其过程可靠预后的手段,因此可用于 更好地治疗癌症。 上述方法和试剂盒也可用于评估其他已知的α-和β-胸腺素的测定,如胸腺素β9(Tbeta9),胸腺素β4(Tbeta4),胸腺素β15(Tbeta15),胸腺素α1(Tbeta1), prothymosin(ProTalpha)和parathymosin(ParaTalpha)。
    • 5. 发明申请
    • CANCER PROGNOSIS USING THYMOSIN DOLLAR G(B)10 (T DOLLAR G(B)10)
    • 使用甲氨喋呤G(B)10(T DOLLAR G(B)10)的癌症预防
    • WO03046582A2
    • 2003-06-05
    • PCT/GR0200060
    • 2002-11-28
    • NAT CT SCIENT RES DEMOKRITOSFARAN LAB S AAPOSTOLIKAS NIKIFOROSEVANGELATOS GRIGORIOSITHAKISSIOS XANTHI HFLEONDIADIS LEONDIOSLIVANIOU EVANGELIAVERGHESE-NIKOLAKAKI SUSANA
    • APOSTOLIKAS NIKIFOROSEVANGELATOS GRIGORIOSITHAKISSIOS DIONYSIOS DILEONDIADIS LEONDIOSLIVANIOU EVANGELIAVERGHESE-NIKOLAKAKI SUSANA
    • G01N33/574G01N33/68
    • G01N33/574G01N2333/5759
    • The invention presents a reliable specific immunohistochemical method, which uses thymosin beta 10 as a cancer marker with application in the confirmation of diagnosis and prognosis of cancer, and provides guidance for the evaluation of positivity of immunohistochemical expression of thymosin beta 10 in benign and malignant tissues. The evaluation of the measured T beta 10 expression is characterized by the fact that T beta 10 expression is correlated with the aggressiveness of the disease, and this correlation is based on the concept that: the weaker the expression of T beta 10 in cancer cells, the higher the aggressiveness of the neoplasm and vice versa, that is: the stronger the expression of T beta 10 in cancer cells, the lower the aggressiveness of the neoplasm. The invention also describes an in vitro diagnostic kit, which, by application of the above-described concept of evaluation of T beta 10 expression, provides a means of confirmation of cancer diagnosis and a means of reliable prognosis of its course, and is therefore useful for the better therapeutic handling of cancer. The above method and kit are also applicable in the evaluation of the measurement of other known alpha - and beta -thymosins, such as thymosin beta 9 (T beta 9), thymosin beta 4 (T beta 4), thymosin beta 15 (T beta 15), thymosin alpha 1 (T beta 1), prothymosin (ProT alpha ) and parathymosin (ParaT alpha ).
    • 本发明提供了一种可靠的特异性免疫组织化学方法,其使用胸腺素β10作为癌症标志物,用于确认癌症的诊断和预后,并为胸腺素β10在良性和恶性组织中的免疫组织化学表达阳性的评价提供指导 。 测量的Tβ10表达的评估的特征在于Tβ10表达与疾病的侵袭性相关,并且这种相关性基于以下概念:T细胞在癌细胞中的表达越弱, 肿瘤的侵袭性越高,反之亦然,即:T细胞癌在癌细胞中的表达越强,肿瘤的侵袭性越低。 本发明还描述了一种体外诊断试剂盒,其通过应用上述Tβ10表达评估概念提供了确认癌症诊断的方法和其当然可靠的预后手段,因此是有用的 为了更好地治疗癌症。 上述方法和试剂盒也可用于评估其他已知的α-和β-胸腺素的测定,例如胸腺素β9(Tβ9),胸腺素β4(Tβ4),胸腺素β15(Tβ 15),胸腺素α1(Tβ1),孕激素(ProTα)和对映体蛋白(ParaTα)。